Successful application of extracorporeal membrane oxygenation due to pulmonary hemorrhage secondary to granulomatosis with polyangiitis
Author(s) -
Paul Zarogoulidis,
Wolfgang HohenforstSchmidt,
Arndt T. Petermann,
Ketteler,
Visouli,
Darwiche,
Nikoalos Machairiotis,
Kougioumtzi,
Kosmas Tsakiridis,
Brachmann
Publication year - 2013
Publication title -
drug design development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s47156
Subject(s) - medicine , extracorporeal membrane oxygenation , pulmonary hemorrhage , respiratory failure , plasmapheresis , granulomatosis with polyangiitis , diffuse alveolar hemorrhage , renal replacement therapy , life support , surgery , dialysis , contraindication , lung , intensive care medicine , disease , vasculitis , antibody , immunology , alternative medicine , pathology
Extracorporeal membrane oxygenation (ECMO) is increasingly applied in adults with acute refractory respiratory failure that is deemed reversible. Bleeding is the most frequent complication during ECMO support. Severe pre-existing bleeding has been considered a contraindication to ECMO application. Nevertheless, there are cases of successful ECMO application in patients with multiple trauma and hemorrhagic shock or head trauma and intracranial hemorrhage. ECMO has proved to be life-saving in several cases of life-threatening respiratory failure associated with pulmonary hemorrhage of various causes, including granulomatosis with polyangiitis (Wegener's disease). We successfully applied ECMO in a 65-year-old woman with acute life-threatening respiratory failure due to diffuse massive pulmonary hemorrhage secondary to granulomatosis with polyangiitis, manifested as severe pulmonary-renal syndrome. ECMO sustained life and allowed disease control, together with plasmapheresis, cyclophosphamide, corticoids, and renal replacement therapy. The patient was successfully weaned from ECMO, extubated, and discharged home. She remains alive on dialysis at 17 months follow-up.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom